Q3 2026 Earnings Estimate for Neogen Co. (NASDAQ:NEOG) Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG) – Investment analysts at Zacks Research boosted their Q3 2026 earnings estimates for shares of Neogen in a research report issued to clients and investors on Tuesday, April 30th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.17 per share for the quarter, up from their previous forecast of $0.16. The consensus estimate for Neogen’s current full-year earnings is $0.46 per share. Zacks Research also issued estimates for Neogen’s FY2026 earnings at $0.65 EPS.

Neogen (NASDAQ:NEOG) last posted its earnings results on Tuesday, April 9th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.02). The business had revenue of $228.80 million during the quarter, compared to the consensus estimate of $230.01 million. Neogen had a net margin of 0.17% and a return on equity of 3.35%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.12 EPS.

Separately, Piper Sandler decreased their price target on Neogen from $19.00 to $17.00 and set a “neutral” rating on the stock in a research note on Monday, April 15th.

Neogen Trading Down 3.5 %

NEOG stock opened at $12.02 on Friday. Neogen has a 1-year low of $11.46 and a 1-year high of $24.09. The company has a current ratio of 3.82, a quick ratio of 2.66 and a debt-to-equity ratio of 0.28. The business’s 50 day moving average is $14.41 and its 200-day moving average is $16.22. The firm has a market cap of $2.60 billion, a P/E ratio of 1,203.20 and a beta of 1.18.

Insider Buying and Selling at Neogen

In other Neogen news, COO Douglas Edward Jones bought 10,000 shares of Neogen stock in a transaction dated Wednesday, April 17th. The shares were acquired at an average cost of $12.36 per share, with a total value of $123,600.00. Following the acquisition, the chief operating officer now directly owns 46,131 shares of the company’s stock, valued at $570,179.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Neogen news, COO Douglas Edward Jones bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, April 17th. The shares were bought at an average price of $12.36 per share, for a total transaction of $123,600.00. Following the completion of the acquisition, the chief operating officer now owns 46,131 shares of the company’s stock, valued at $570,179.16. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James C. Borel purchased 7,500 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average cost of $13.06 per share, with a total value of $97,950.00. Following the completion of the acquisition, the director now directly owns 21,392 shares of the company’s stock, valued at $279,379.52. The disclosure for this purchase can be found here. Insiders have bought a total of 53,000 shares of company stock worth $662,205 over the last ninety days. Corporate insiders own 0.71% of the company’s stock.

Hedge Funds Weigh In On Neogen

A number of large investors have recently modified their holdings of the stock. Mutual of America Capital Management LLC raised its position in Neogen by 17.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 280,396 shares of the company’s stock worth $4,425,000 after purchasing an additional 42,020 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of Neogen by 3.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 84,724 shares of the company’s stock valued at $1,337,000 after buying an additional 2,583 shares during the period. BNP Paribas Financial Markets raised its position in shares of Neogen by 73.4% during the first quarter. BNP Paribas Financial Markets now owns 115,830 shares of the company’s stock worth $1,828,000 after acquiring an additional 49,041 shares during the last quarter. Baillie Gifford & Co. lifted its stake in shares of Neogen by 42.3% during the first quarter. Baillie Gifford & Co. now owns 11,789,521 shares of the company’s stock valued at $186,039,000 after acquiring an additional 3,502,807 shares during the period. Finally, Hartline Investment Corp bought a new position in Neogen in the first quarter valued at about $234,000. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.